Search Results

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.

The acquisition expands scalable trial operations across real-world care settings

DIA’s Medical Affairs and Scientific Communications Forum brings together medical affairs professionals to share best practices, tackle current challenges, and drive innovation in healthcare communication. What to Expect: Three specialized tracks: medical communications, medical writing, and field medical Roundtable discussions and real-world case studies you can apply immediately Poster sessions featuring original research DIA Community Meet-ups and networking receptions Exhibit hall showcasing innovative technologies and solutions Why Attend: Connect with like-minded professionals, gain practical insights on regulatory compliance and strategic communications, and build cross-functional relationships that enhance your impact. Designed by medical affairs practitioners, for practitioners.

On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.

Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.